Australia: Amendments to a patent during court proceedings – how much transparency is required?

In Apotex Pty Ltd v ICOS Corporation [2017] FCA 466, the Federal Court has provided guidance regarding the level of disclosure required by a patentee in order for a court to exercise its discretion in allowing amendments to the specification during court proceedings.

Eli Lilly and Company (Lilly) is the holding company of ICOS Corporation (ICOS) and holds a number of patents worldwide that relate to a compound known as tadalafil (a PDE5 inhibitor that is useful in the treatment of erectile dysfunction).

As part of a Federal Court proceeding brought by Apotex relating to the validity of AU 773666 (the "666 Patent", relating to compositions containing tadalafil, including in micronised particle sizes, and methods of treatment using such compositions) and the AU 769946 (the "946 Patent", relating to compositions containing particular daily dosages of tadalafil for oral administration and methods of treatment using such dosages), ICOS sought orders to amend the specifications of the patents under s105(1) of the Patents Act 1990 (which deals with court-directed amendments).

The proposed amendments to the 666 Patent involved the addition of 15 dependent claims directed to specific doses or dosage ranges of tadalafil. The purpose of these amendments was to strengthen ICOS's defence to Apotex's inventive step challenge.

The proposed amendments to the 946 Patent involved removing statements in the specification concerning the side effect profile of tadalafil when co-administered with organic nitrates. One of the grounds of invalidity raised by Apotex was inutility on the basis that tadalafil did not eliminate particular side effects, or reduce them to clinically insignificant levels, when co-administered with an organic nitrate. The purpose of the amendments was to strengthen ICOS's defence to Apotex's utility challenge by removing any promises that could be found to have not been met (in Ronneby Road Pty Ltd v ESCO Corporation [2016] FCA 588, Jessup J found that failure of one of the promised results, even though others were attained, could give rise to revocation for inutility).

Apotex opposed the amendments for both the 666 Patent and the 946 Patent, arguing that ICOS had failed to make full disclosure of all relevant matters relating to the proposed amendments, that it had unreasonably delayed the proposed amendments, and that it had not adequately explained the reasons for the proposed amendments (Apotex subsequently withdrew their opposition to the amendments for the 666 Patent).

The Commissioner of Patents found that the amendments to the 666 Patent and the 946 Patent met the requirements of s102 of the Act (which deals with amendments which are not allowable). As such, the only issue was whether the amendments should be allowed in the exercise of the Court's discretion.

The relevant principles in relation to an application to amend a patent under s105(1) have been previously summarised by the Full Federal Court in Laboratoires Servier v Apotex Pty Ltd [2016] FCAFC 27; (2016) 117 IPR 415. In that case, the Court refused to allow the patentee to amend its specification to overcome a failure to describe the best known method of working the invention. The relevant principles established in that case were:

  • the onus to establish that amendment should be allowed is on the patentee;
  • generally, a permissible amendment (i.e. one which is permitted under s102 of the Act) will be allowed unless there are circumstances which would lead the court to refuse amendment;
  • the patentee must make full disclosure of all relevant matters;
  • amendment should be sought promptly and where a patentee delays for an unreasonable period, the patentee has the onus of showing that it delayed on reasonable grounds;
  • unreasonable delay is a circumstance likely to lead to refusal of an amendment;
  • in assessing delay, the relevant time is from when the patentee knows of the likely invalidity, or has its attention drawn to a defect in the patent, or is advised to strengthen the patent by amendment;
  • mere delay is not, of itself, sufficient to refuse to exercise the discretion to amend. The fact of delay is, however, relevant to whether the respondent or the general public have suffered detriment; and
  • if a patentee seeks to take unfair advantage of the unamended patent, knowing that it requires amendment, then refusal of the amendment is likely.

ICOS relied on affidavits sworn by Mr Gary Cox (lawyer and patent attorney at Wrays, acting for ICOS), Dr Mark Stewart (patent attorney at Lilly), Mr Danny Wood (patent attorney at Lilly), and Dr Malcolm Mitchel (formerly Medical Director at Lilly) setting out, in detail, the reasons for the proposed amendments to the 666 Patent and the 946 Patent, and the timing of events leading up to the application to amend. ICOS also provided verified discovery which included emails between Wrays and Lilly, emails between internal Lilly patent counsel and Lilly's clinical study reports. ICOS did not maintain a claim for privilege in respect of these documents.

The Court found that ICOS's conduct was reasonable, that it had made full disclosure and that there had been no unreasonable delay in seeking to amend the specifications of the the 666 Patent and the 946 Patent. The Court also found that there was no evidence that Apotex would suffer any prejudice if the amendments were allowed, other than the possible effect on its utility challenge. Apotex had given an undertaking not to market, sell or exploit its generic tadalafil products during the term of AU 689205 (Lily's tadalafil composition patent), so the patents which ICOS sought to amend had not been instrumental in Apotex refraining from entering the market. In addition, the Court noted that the application to amend had been made before trial, and that no third party had sought to oppose the application to amend.

Apotex identified four matters which it submitted were relevant to the Court's exercise of its discretion.

Firstly, Apotex submitted that the amendments to the 946 Patent did not involve a narrowing of the claims so as to avoid an argument based on a piece of prior art. Rather, they involved the removal of statements about the co-administration of tadalafil and organic nitrates. Apotex submitted that the obligation to make promises that were met or could be met crystallised on the filing of the patent application or, in the alternative, on the grant of the patent. However, the Court found that unlike best method and sufficiency, the patentee was not required to make statements regarding the utility of the invention, so that no such obligation crystallised on filing.

Secondly, Apotex argued that ICOS's conduct in relying on statements about the co administration of tadalafil and organic nitrates in correspondence with the Commissioner of Patents during prosecution of the 946 Patent should be taken into account and was a reason not to allow the amendments. However, the Court was not satisfied that the statements made by ICOS during prosecution were material in overcoming the objections raised by the examiner.

Thirdly, Apotex argued that the amendments sought by ICOS involved the removal of the main promises in the 946 Patent. However, the Court found that while the statements about the co-administration of tadalafil and organic nitrates were an important aspect of the specification, they were not the only advantage identified.

Fourthly, Apotex argued that the 946 Patent is a selection patent and that the advantages of the selected members are critical to the validity of the patent. However, the Court found that even if the 946 Patent is a selection patent and the amendments are allowed, a number of advantages or benefits of the invention remain in the specification.

The Court was not satisfied that the matters identified by Apotex warranted a refusal of the application to amend. Consequently the Court directed that, pursuant to s105(1), the complete specification of the 666 Patent and the 946 Patent be amended. The invalidity trial is listed for June 2017 and Shelston IP will keep you informed of developments.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP ranked one of Australia's leading Intellectual Property firms in 2015.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Katrina Crooks
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.